BNP Paribas Financial Markets’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-584,192
| Closed | -$23.5M | – | 5912 |
|
|
2026
Q1 | $23.5M | Buy |
584,192
+26,601
| +5% | +$573K | 0.01% | 1050 |
|
|
2025
Q4 | $14M | Sell |
557,591
-414,883
| -43% | -$9.73M | 0.01% | 1403 |
|
|
2025
Q3 | $22M | Sell |
972,474
-325,985
| -25% | -$7.6M | 0.01% | 1068 |
|
|
2025
Q2 | $22.5M | Buy |
1,298,459
+187,750
| +17% | +$3.48M | 0.01% | 986 |
|
|
2025
Q1 | $24.3M | Buy |
1,110,709
+259,886
| +31% | +$7.18M | 0.01% | 943 |
|
|
2024
Q4 | $27.1M | Buy |
850,823
+691,123
| +433% | +$20.8M | 0.02% | 880 |
|
|
2024
Q3 | $4.61M | Buy |
159,700
+55,282
| +53% | +$2.05M | ﹤0.01% | 1549 |
|
|
2024
Q2 | $4.01M | Buy |
104,418
+52,792
| +102% | +$2.39M | ﹤0.01% | 1528 |
|
|
2024
Q1 | $3.03M | Sell |
51,626
-115,862
| -69% | -$7.39M | ﹤0.01% | 1798 |
|
|
2023
Q4 | $10M | Sell |
167,488
-68,867
| -29% | -$3.49M | 0.01% | 1024 |
|
|
2023
Q3 | $8.99M | Buy |
236,355
+177,694
| +303% | +$7.81M | 0.01% | 948 |
|
|
2023
Q2 | $5.34M | Sell |
58,661
-57,969
| -50% | -$5M | 0.01% | 1207 |
|
|
2023
Q1 | $7.69M | Buy |
116,630
+80,434
| +222% | +$4.64M | 0.01% | 1031 |
|
|
2022
Q4 | $1.87M | Sell |
36,196
-79,166
| -69% | -$4.2M | ﹤0.01% | 1806 |
|
|
2022
Q3 | $7.88M | Buy |
115,362
+95,294
| +475% | +$5.64M | 0.01% | 1110 |
|
|
2022
Q2 | $907K | Buy |
20,068
+13,717
| +216% | +$625K | ﹤0.01% | 2264 |
|
|
2022
Q1 | $323K | Sell |
6,351
-8,586
| -57% | -$379K | ﹤0.01% | 2962 |
|
|
2021
Q4 | $706K | Buy |
14,937
+3,497
| +31% | +$138K | ﹤0.01% | 2818 |
|
|
2021
Q3 | $377K | Buy |
11,440
+9,137
| +397% | +$513K | ﹤0.01% | 2855 |
|
|
2021
Q2 | $146K | Sell |
2,303
-5,199
| -69% | -$268K | ﹤0.01% | 2937 |
|
|
2021
Q1 | $322K | Sell |
7,502
-581
| -7% | -$27.5K | ﹤0.01% | 2812 |
|
|
2020
Q4 | $462K | Sell |
8,083
-6,070
| -43% | -$257K | ﹤0.01% | 2502 |
|
|
2020
Q3 | $427K | Buy |
14,153
+6,859
| +94% | +$205K | ﹤0.01% | 2313 |
|
|
2020
Q2 | $238K | Sell |
7,294
-22,699
| -76% | -$729K | ﹤0.01% | 2423 |
|
|
2020
Q1 | $804K | Sell |
29,993
-21,740
| -42% | -$772K | ﹤0.01% | 2077 |
|
|
2019
Q4 | $1.58M | Buy |
51,733
+44,401
| +606% | +$1.23M | ﹤0.01% | 1789 |
|
|
2019
Q3 | $177K | Buy |
7,332
+3,294
| +82% | +$90.7K | ﹤0.01% | 2822 |
|
|
2019
Q2 | $102K | Sell |
4,038
-3,481
| -46% | -$70.8K | ﹤0.01% | 3021 |
|
|
2019
Q1 | $147K | Buy |
7,519
+7,516
| +250,533% | +$118K | ﹤0.01% | 2886 |
|
|
2018
Q4 | $40 | Sell |
3
-1,179
| -100% | -$18.1K | ﹤0.01% | 4261 |
|
|
2018
Q3 | $21K | Hold |
1,182
| – | – | ﹤0.01% | 3398 |
|
|
2018
Q2 | $26K | Sell |
1,182
-773
| -40% | -$17.8K | ﹤0.01% | 3390 |
|
|
2018
Q1 | $43.2K | Sell |
1,955
-295
| -13% | -$5.8K | ﹤0.01% | 3635 |
|
|
2017
Q4 | $48.8K | Buy |
+2,250
| New | +$33.1K | ﹤0.01% | 3671 |
|
Other funds holding APLS
BNP Paribas Financial Markets's APLS Position: Q2 2026 in Review
BNP Paribas Financial Markets sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 584,192 shares — an estimated $23.5M sold.
BNP Paribas Financial Markets first reported a position in APLS in Q4 2017 and held it in 34 quarters. The position peaked at $27.1M in Q4 2024. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- BNP Paribas Financial Markets reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- BNP Paribas Financial Markets sold 584,192 Apellis Pharmaceuticals shares in Q2 2026, an estimated $23.5M.
- BNP Paribas Financial Markets first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 34 quarters.
- BNP Paribas Financial Markets's Apellis Pharmaceuticals position peaked at $27.1M in Q4 2024.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.